Largest Real-World Analysis of Ivermectin + Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit — Nearly HALF Report Cancer Disappearance or Regression

 We have completed the largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients — and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: "Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort."

In this real-world prospective clinical program evaluation, a diverse population of cancer patients (n=197) were prescribed compounded ivermectin-mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.

At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR), with nearly half of cancer patients (48.4%) reporting either no evidence of disease (32.8%) or tumor regression (15.6%). An additional 36.1% reported disease stabilization. This means more than four out of five patients reported either improvement or stabilization of their cancer....<<<Read More>>>...